In summary, our research demonstrated that inhibiting the aberrant upregulation of TMEM16A could reverse ischemia-induced BBB injury by downregulating ICAM-1 levels in an NF-κB signaling dependent manner. The gene discussed is NFKB1; the disease is ischemia.